Literature DB >> 19930211

Idiopathic intracranial hypertension.

S Dhungana1, B Sharrack, N Woodroofe.   

Abstract

Idiopathic intracranial hypertension (IIH) is a condition which affects predominantly overweight women and is characterized by raised intracranial pressure without any identifiable pathology in the brain and with normal cerebrospinal fluid (CSF) composition. The cause of IIH is unclear and as such it remains a diagnosis of exclusion. Although the pathophysiology of IIH remains elusive, some observations have recently been added to our understanding of this, including the presence of transverse sinus stenosis on many patients and the possible role of leptin and inflammation in the disease pathogenesis. Headache is the most common symptom and papilloedema is the major clinical finding. Choices of medical treatment are limited to the use of diuretics particularly acetazolamide and encouragement of weight loss. Surgical therapies such as CSF diversion procedures and fenestration of the optic nerve may be necessary in some cases with persistent symptoms or progressive visual deterioration. While not life-threatening, IIH has a significant morbidity with up to 25% of patients developing visual impairment from optic atrophy. Visual surveillance is therefore vital. Long-term follow-up is recommended as the disease may worsen after an initial period of stability.

Entities:  

Mesh:

Year:  2009        PMID: 19930211     DOI: 10.1111/j.1600-0404.2009.01172.x

Source DB:  PubMed          Journal:  Acta Neurol Scand        ISSN: 0001-6314            Impact factor:   3.209


  24 in total

1.  Absence of aquaporin-4 antibodies in patients with idiopathic intracranial hypertension.

Authors:  Samish Dhungana; Patrick Waters; Azza Ismail; Nicola Woodroofe; Angela Vincent; Basil Sharrack
Journal:  J Neurol       Date:  2010-03-16       Impact factor: 4.849

2.  Idiopathic intracranial hypertension in a patient with thyroid papillary carcinoma.

Authors:  A Carotenuto; F Barbato; G Vacca; F Barbieri; G Orefice
Journal:  Neurol Sci       Date:  2013-07-14       Impact factor: 3.307

3.  Increased levels of interleukins 2 and 17 in the cerebrospinal fluid of patients with idiopathic intracranial hypertension.

Authors:  Laura J Edwards; Basil Sharrack; Azza Ismail; Christopher R Tench; Bruno Gran; Samish Dhungana; Johannes Brettschneider; Hayrettin Tumani; Cris S Constantinescu
Journal:  Am J Clin Exp Immunol       Date:  2013-10-16

4.  The incidence of idiopathic intracranial hypertension in Scotland: a SOSU study.

Authors:  Colin Goudie; Pushkar Shah; Justin McKee; Barny Foot; Obaid Kousha; Andrew Blaikie
Journal:  Eye (Lond)       Date:  2019-04-30       Impact factor: 3.775

5.  Use of Phase-Contrast MRA to Assess Intracranial Venous Sinus Resistance to Drainage in Healthy Individuals.

Authors:  S Fall; G Pagé; J Bettoni; R Bouzerar; O Balédent
Journal:  AJNR Am J Neuroradiol       Date:  2016-12-08       Impact factor: 3.825

6.  Visual Outcomes from Shunting for Idiopathic Intracranial Hypertension.

Authors:  S J Hickman; N Raoof; H Panesar; J M McMullan; I M Pepper; B Sharrack
Journal:  Neuroophthalmology       Date:  2014-11-12

Review 7.  Idiopathic intracranial hypertension in the Middle East: A growing concern.

Authors:  Sumayya J Almarzouqi; Michael L Morgan; Andrew G Lee
Journal:  Saudi J Ophthalmol       Date:  2014-09-28

8.  Bilateral transverse sinus stenosis in patients with tinnitus.

Authors:  G Chiarella; F Bono; C Cassandro; M Lopolito; A Quattrone; E Cassandro
Journal:  Acta Otorhinolaryngol Ital       Date:  2012-08       Impact factor: 2.124

9.  Idiopathic intracranial hypertension as the initial presentation of systemic lupus erythematosus.

Authors:  Chandrasekharan Rajasekharan; Sanu Watson Renjith; Ali Marzook; Rajasekharan Parvathy
Journal:  BMJ Case Rep       Date:  2013-01-31

Review 10.  Idiopathic intracranial hypertension occurred after spinal surgery: report of two rare cases and systematic review of the literature.

Authors:  Zhengkuan Xu; Hao Li; Gang Chen; Fangcai Li; Shenjun Qian; Qixin Chen
Journal:  Eur Spine J       Date:  2016-05-17       Impact factor: 3.134

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.